Prevention of venous thrombosis after elective hip surgery

Orthopedics

Volumn 21, Issue 12, 1998, Pages 1275-1281

  Turpie, A G G ^a,c   Kher, A ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b Euthemis   (France)

^c HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ARDEPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

ANTICOAGULANT THERAPY; HEPARINIZATION; HIP SURGERY; HUMAN; POSTOPERATIVE COMPLICATION; PROPHYLAXIS; REVIEW; VEIN THROMBOSIS;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; CLINICAL TRIALS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PULMONARY EMBOLISM; SURGICAL PROCEDURES, ELECTIVE; SURVIVAL RATE; THROMBOPHLEBITIS; TREATMENT OUTCOME;

EID: 0032439495     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Thromboprophylaxis in orthopaedic surgery. Orthopaedics International. 1993; 1:396-402
2. Consensus Conference. Prevention of venous thrombosis and pulmonary embolism. JAMA. 1986; 256:744-749.
3. Fourth ACCP Consensus Conference on Antithrombotic Therapy. Chest. 1995; 108:225S-522S.
4. Barre J, Pfister G, Potron G, et al. Efficacite et tolerance du Kabi 2165 et de l'heparine standard dans la prevention des thromboses veineuses profondes au cours des protheses totales de hanche. J Mal Vasc. 1987; 12:90-95.
5. Eriksson BI, Zochrisson BE, Teger-Nilsson AL, et al. Thrombosis prophylaxis with low molecular weight heparin in total hip replacement. Br J Surg. 1988; 75:1053-1057.
6. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost. 1988; 60:407-410.
7. Dechavanne M, Ville D, Berruyer M, et al. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted dose subcutaneous standard heparin in the prophylaxis of deep vein thrombosis after elective hip surgery. Haemostasis. 1989; 19:5-12.
8. Eriksson BI, Kalebo P, Anthmyr BA, et al. Prevention of deep vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg Am. 1991; 73:484-493.
9. Torholm C, Broeng L, Seest Jorgensen P, et al. Thromboprophylaxis by low molecular weight heparin in elective hip surgery. J Bone Joint Surg Br. 1991; 73:434-438.
10. Leyvraz PF, Bachmann F, Hoek, et al. Prevention of deep vein thrombosis after hip replacement; randomized comparison between unfractionated heparin and low molecular weight heparin. Br Med J. 1991; 303:543-548.
11. Danish Enoxaparin Study Group. Low molecular weight heparin (enoxaparin) vs dextran 70; the prevention of postoperative deep vein thrombosis after total hip replacement. Arch Intern Med. 1991; 151:1621-1624.
12. German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low molecular weight heparin in patients undergoing total hip replacement: a randomized trial. Archives of Orthopaedic Surgery. 1992; 111:110-120.
13. Hamulyak K, Lensing AW, Van Der Meer J, et al for the Fraxiparine Oral Anticoagulant Study Group. Subcutaneous low molecular weight heparin or oral anticoagulants for the prevention of deep vein thrombosis in elective hip and knee replacement. Thromb Haemost. 1994; 74:1428-1434.
14. Turpie AGG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low molecular weight heparin (enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986; 315:925-929.
15. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin and standard unfractionated heparin. Ann Intern Med. 1991; 114:545-551.
16. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep vein thrombosis after hip or knee implantation. N Engl J Med. 1993; 329:1370-1376.
17. Spiro TE, Johnson GJ, Christie MJ, et al for the Enoxaparin Clinical Trial Group. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Ann Intern Med. 1994; 121:81-89.
18. Colwell CW, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low molecular weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement - a clinical trial comparing efficacy and safety. J Bone Joint Surg Am. 1994; 76:3-14.
19. RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am. 1994; 76:1174-1185.
20. European Consensus Statement, Windsor UK. Prevention of venous thromboembolism. International Angiology. 1992; 11:151-159.
21. Bergqvist D, Linblad B. A 30-year old survey of pulmonary embolism verified at autopsy: an analysis of 1274 surgical patients. Br J Surg. 1985; 72:105-108.
22. Sevitt S. Venous thrombosis and pulmonary embolism. Their prevention by oral anticoagulants. Am J Surg. 1962; 33:703-716.
23. Johnson R, Green RJ, Charnley J. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement. Clin Orthop. 1977; 127:123-132.
24. Hampson WGJ, Harris BC, Oucas K, et al. Failure of low dose heparin to prevent deep vein thrombosis after hip replacement arthroplasty. Lancet. 1974; 2:795-799.
25. Mannucci PM, Citterio LE, Panajotopoulos N. Low dose heparin and deep vein thrombosis after hip replacement. Thromb Haemost. 1976; 36:157-164.
26. Sikowski JM, Hampson WG, Staddon GE. The natural history and etiology of deep vein thrombosis after total hip replacement. J Bone Joint Surg. 1981; 63:171-177.
27. Fricker JP, Vergnes Y, Schach R, et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest. 1988; 18:561-567.
28. Flinn WR, Sandager GP, Cerullo IJ, et al. Duplex venous scanning for the perspective surveillance of perioperative venous thrombosis. Arch Surg. 1989; 124:901-905.
29. Kraay MJ, Goldberg VM, Herbener TE. Vascular ultrasonography for deep venous thrombosis after total knee arthroplasty. Clin Orthop. 1993; 286:18-26.
30. Trowbridge A, Boese CK, Woodruff B, et al. Incidence of post-hospitalization proximal deep venous thrombosis after total hip arthroplasty. Clin Orthop. 1994; 299:203-208.
31. Scurr JH. How long after surgery does the risk of thromboembolism persist. Acta Chirurgica Scandinavica. 1990; 556:22-24.
32. Huber O, Bounameaux H, Borst F, et al. Postoperative pulmonary embolism after hospital discharge; an underestimated risk. Arch Surg. 1992; 127:310-313.
33. Woolson ST, McRory D, Walter JF, et al. B-mode ultrasound scanning in the detection of proximal venous thrombosis after hip replacement. J Bone Joint Surg Am. 1990; 72:983-987.
34. Agnelli G, Ranucci V, Cosmi E, et al. Outcome of hip surgery in patients with lower limb-negative venography at discharge. Thromb Haemost. 1991; 65:1175.
35. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet. 1993; 341:259-265.
36. Paiement GD, Wessinger SJ, Harris WH. Survey of prophylaxis against venous thromboembolism in adults undergoing hip surgery. Clin Orthop. 1987; 223:188-193.
37. Laverick MD, Croal SA, Mollan RA. Orthopedic surgeons and thromboprophylaxis. Br Med J. 1991; 303:549-550.
38. Planes A, Coehelle N, Darmon JY, et al. Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomized comparison of enoxaparin versus placebo. Lancet. 1996; 348:224-228.
39. Dahl OE, Andreassen G, Muller C, et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thromb Haemost. 1995; 73:1094.
40. Bergqvist D, Benoni G, Bjorgell O, et al. Low molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996; 335:696-700.
41. Lassen MR, Borris LC on behalf of the Danish Prolonged Prophylaxis Study Group. Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty - a placebo controlled study. Thromb Haemost. 1995; 73:1104.
42. Warwick D, Williams MH, Bannister GC. Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg Br. 1995; 77:6-10.
43. Bergqvist D. Review of clinical trials of low molecular weight heparins. Eur J Surg. 1992; 158:67-78.
44. Jorgensen LN, Wille-Jorgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg. 1993; 80:689-704.
45. Murray DW, Britton AR, Bulstrode CJK. Thromboprophylaxis and death after total hip replacement. J Bone Joint Surg Br. 1996; 78:863-870.